newsfilter
← Latest News
PR Newswire·

Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions Seribantumab granted Fast Track designation by FDA for